Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvortuxizumab + Ibrutinib in B-Cell Malignancies
NCT02743546Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2016
- Primary completion
- Sep 2018
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of duvortuxizumab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and 1 more (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Dose Limiting Toxicity at 9 months, Number of Participants With Adverse Events at 2 years and 2 more. Planned start Jul 2016; status: withdrawn.
02
Drugs
duvortuxizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02743546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02743546.